Health Research Methods, Evidence, and Impact


Pendar Farahani

MD (TUMS), MSc (McMaster), F.R.C.P.C., D.A.B.I.M., F.A.C.P.

Assistant Professor (Part-time), Department of Health Research Methods, Evidence, and Impact

University Scientist, Programs for Assessment of Technology in Health (PATH) Research Institute Medical

Consultant in Diabetes, Endocrinology & Metabolism, GTA, Ontario, Canada

Phone: 905-523-7284
Email: farahanp@mcmaster.ca

Programs for Assessment of Technology in Health (PATH)
25 Main St. West, Suite 2000
Hamilton, ON L8P 1H1
Canada

 

Academic Interests

As an endocrinologist, clinical pharmacologist, and epidemiologist, Dr. Farahani developed a combined research interest with a focus on pharmacoepidemiology, pharmacoeconomics, and individualized pharmacotherapy in the fields of diabetes, metabolism and endocrinology. His research interests include evaluation of therapeutics in real-world clinical settings and community-based practices from effectiveness, safety/risk management and economic perspectives. He is interested in assessment of contributing factors that can impact pharmacotherapy in real-world clinical settings, which are not captured by RCTs, such as medical comorbidities, aging, sex/gender, ethnicity, socioeconomic status, education, geographic area, and healthcare systems. He is also interested in research studies to enhance and develop combination pharmacotherapy strategies with medical technologies/devices for diabetes care, models for diabetes care, and clinical pharmacology studies in real world settings.

Selected Publications

  1. Farahani P, Khan S, Oatway M, Dziarmaga A. Exploring the distribution of prescription/utilization for sulfonylureas in patients with type 2 diabetes according to cardiovascular risk factors within a Canadian primary care setting. Journal of Population Therapeutics and Clinical Pharmacology, Nov 11, 2015; 22(3):e228-36
  2. Farahani P. Challenges in pharmacotherapeutics education for diabetes in real-world clinical settings: views from family medicine and internal medicine residents. Clin Invest Med 2015;38:E73-E81.
  3. Farahani P, Levine M. Household income and LDL-C goal attainment in patients with diabetes and dyslipidemia in a Canadian dataset. Clin Invest Med 2014;37:E47-E52.
  4. Farahani P. Sex/gender disparities in randomized controlled trials of statins: the impact of awareness efforts. Clin Invest Med 2014;37:E163-E171.
  5. Farahani P. A Perspective on Principles of Comparative Cost-Effectiveness Studies for Pharmacotherapy of Chronic Diseases. Clinical Diabetes 2012;30:54-60.
  6. Farahani P, Levine M. Goal attainment for multiple cardiovascular risk factors in community-based clinical practice (a Canadian experience). J Eval Clin Pract 2009;15:212-216.
  7. Farahani P, Levine M, Gaebel K et al. Exploring patient demographic and clinical characteristics associated with lipid-lowering pharmacotherapy use in primary care. Clin Invest Med 2007;30:E63-E69.
  8. Farahani P, Levine M, Goeree R. A comparison between integrating clinical practice setting and randomized controlled trial setting into economic evaluation models of therapeutics. J Eval Clin Pract 2006;12:463-470.
  9. Farahani P, Levine M, Gaebel K, Wang EC, Khalidi N. Community-based evaluation of etanercept in patients with rheumatoid arthritis. J Rheumatol 2006;33:665-670.
  10. Farahani P, Levine M, Gaebel K, Thabane L. Clinical data gap between phase III clinical trials (pre-marketing) and phase IV (post-marketing) studies: evaluation of etanercept in rheumatoid arthritis. Can J Clin Pharmacol 2005;12:e254-e263.

Search for citations for Dr. Farahani on PubMed